Aapro M S
Division of Medical Oncology, European Institute of Oncology, Milano, Italy.
Recent Results Cancer Res. 1996;142:425-30. doi: 10.1007/978-3-642-80035-1_24.
From the contributions in this volume, it is apparent that in spite of promising chemotherapy combinations and new multidisciplinary approaches, the treatment of advanced gastrointestinal malignancies remains a difficult task. New agents have recently been developed with either a better therapeutic ratio (fluoropyrimidine analogs or modulators of the metabolic pathway of those agents) or a better activity due to a different mechanism of action. Among the latter agents, the topoisomerase I inhibitors (especially irinotecan, also known as CPT-11) and new antimetabolities (difluorodeoxycytidine, also known as gemcitabine) are of interest for difficult tumors, such as colon and pancreatic cancer. This short review describes the phase II studies on the activity of taxoids, agents that promote tubulin assembly in microtubules and inhibit their depolymerization.
从本卷中的文稿可以明显看出，尽管有前景良好的化疗联合方案和新的多学科治疗方法，但晚期胃肠道恶性肿瘤的治疗仍然是一项艰巨的任务。最近已开发出一些新药，它们要么具有更好的治疗指数（氟嘧啶类似物或这些药物代谢途径的调节剂），要么由于不同的作用机制而具有更好的活性。在后者中，拓扑异构酶I抑制剂（尤其是伊立替康，也称为CPT - 11）和新的抗代谢物（二氟脱氧胞苷，也称为吉西他滨）对于结肠癌和胰腺癌等难治性肿瘤很有意义。这篇简短的综述描述了关于紫杉烷类药物活性的II期研究，紫杉烷类药物可促进微管中微管蛋白组装并抑制其解聚。
